CytRx, Galapagos Genomics and Wyeth, Aventis, Genta and Genasense, and Promega and Benitec | GenomeWeb

CytRx Reports Q3 Results, Says Cash Exists to Last Through End of March

CytRx reported this week its financial results for the third quarter, posting no revenues and slightly higher expenses than in the year-ago quarter.

As a result, the company has indicated in a filing with the US Securities and Exchange Commission that it only has enough cash on hand to last through the first quarter of 2005, or until the end of March.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.